Basic Information
RNALocate ID: | RLID:11002211 |
RNA Symbol: | hsa-miR-200c-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-200c-3p |
RNA ID: | miRBase:MIMAT0000617 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001951 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001952 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:01001953 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11002205 | Exosome | Urine | 26576778 |
RLID:11002206 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11002207 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11002208 | Exosome | Ascites fluid|Pleural effusion | 21601258 |
RLID:11002209 | Exosome | Renal cancer cells | 21670082 |
RLID:11002210 | Exosome | Brain tissue | 23382797 |
RLID:11002212 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11002213 | Extracellular vesicle | Plasma | 32498409 |
RLID:11002214 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000105 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue | |
RLID-D:11000392 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-200c-3p | Idiopathic pulmonary fibrosis | MNDR-E-MI-26335 |
MNDR | hsa-miR-200c-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-26336 |
MNDR | hsa-miR-200c-3p | Oral squamous cell carcinoma | MNDR-E-MI-26337 |
MNDR | hsa-miR-200c-3p | Large cell neuroendocrine cancer | MNDR-E-MI-26338 |
MNDR | hsa-miR-200c-3p | B cell lymphoma of malt type | MNDR-E-MI-26339 |
MNDR | hsa-miR-200c-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-26340 |
MNDR | hsa-miR-200c-3p | Ovarian clear cell carcinoma | MNDR-E-MI-26341 |
MNDR | hsa-miR-200c-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-26342 |
MNDR | hsa-miR-200c-3p | Lymphoma | MNDR-E-MI-26343 |
MNDR | hsa-miR-200c-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-26344 |
MNDR | hsa-miR-200c-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-26345 |
MNDR | hsa-miR-200c-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-26346 |
MNDR | hsa-miR-200c-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-26347 |
MNDR | hsa-miR-200c-3p | Her2-receptor positive breast cancer | MNDR-E-MI-26348 |
MNDR | hsa-miR-200c-3p | Triple negative breast cancer | MNDR-E-MI-26349 |
MNDR | hsa-miR-200c-3p | Breast cancer luminal | MNDR-E-MI-26350 |
MNDR | hsa-miR-200c-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-26351 |
MNDR | hsa-miR-200c-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-26352 |
MNDR | hsa-miR-200c-3p | Prostate cancer | MNDR-E-MI-26353 |
MNDR | hsa-miR-200c-3p | Prostate carcinoma | MNDR-E-MI-26354 |
MNDR | hsa-miR-200c-3p | Gastric cancer | MNDR-E-MI-26355 |
MNDR | hsa-miR-200c-3p | Alzheimer disease | MNDR-E-MI-26356 |
MNDR | hsa-miR-200c-3p | Bladder cancer | MNDR-E-MI-26357 |
MNDR | hsa-miR-200c-3p | Dysautonomia familial | MNDR-E-MI-26358 |
MNDR | hsa-miR-200c-3p | Head and neck cancer | MNDR-E-MI-26359 |
MNDR | hsa-miR-200c-3p | Leukemia | MNDR-E-MI-26360 |
MNDR | hsa-miR-200c-3p | Leiomyoma | MNDR-E-MI-26361 |
MNDR | hsa-miR-200c-3p | Huntington disease | MNDR-E-MI-26362 |
MNDR | hsa-miR-200c-3p | Chorea | MNDR-E-MI-26363 |
MNDR | hsa-miR-200c-3p | Cardiovascular disease | MNDR-E-MI-26364 |
MNDR | hsa-miR-200c-3p | Lung cancer | MNDR-E-MI-26365 |
MNDR | hsa-miR-200c-3p | Endometrial cancer | MNDR-E-MI-26366 |
MNDR | hsa-miR-200c-3p | Down syndrome | MNDR-E-MI-26367 |
MNDR | hsa-miR-200c-3p | Parkinson disease | MNDR-E-MI-26368 |
MNDR | hsa-miR-200c-3p | Primary pulmonary hypertension | MNDR-E-MI-26369 |
MNDR | hsa-miR-200c-3p | Breast cancer | MNDR-E-MI-26370 |
MNDR | hsa-miR-200c-3p | Cancer | MNDR-E-MI-26371 |
MNDR | hsa-miR-200c-3p | Thyroid cancer | MNDR-E-MI-26372 |
MNDR | hsa-miR-200c-3p | Pituitary neoplasms | MNDR-E-MI-26373 |
MNDR | hsa-miR-200c-3p | Pancreatic cancer | MNDR-E-MI-26374 |
MNDR | hsa-miR-200c-3p | Hepatitis C | MNDR-E-MI-26375 |
MNDR | hsa-miR-200c-3p | Melanoma | MNDR-E-MI-26376 |
MNDR | hsa-miR-200c-3p | Williams syndrome | MNDR-E-MI-26377 |
MNDR | hsa-miR-200c-3p | Nephroblastoma | MNDR-E-MI-26378 |
MNDR | hsa-miR-200c-3p | Colon cancer | MNDR-E-MI-26379 |
MNDR | hsa-miR-200c-3p | Ischemic attack transient | MNDR-E-MI-26380 |
MNDR | hsa-miR-200c-3p | Colon adenocarcinoma | MNDR-E-MI-26381 |
MNDR | hsa-miR-200c-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-26382 |
MNDR | hsa-miR-200c-3p | Familial ovarian cancer | MNDR-E-MI-26383 |
MNDR | hsa-miR-200c-3p | Acromegaly | MNDR-E-MI-26384 |
MNDR | hsa-miR-200c-3p | Prostate adenocarcinoma | MNDR-E-MI-26385 |
MNDR | hsa-miR-200c-3p | Kidney cancer | MNDR-E-MI-26386 |
MNDR | hsa-miR-200c-3p | Endometrial adenocarcinoma | MNDR-E-MI-26387 |
MNDR | hsa-miR-200c-3p | Endometrial carcinoma | MNDR-E-MI-26388 |
MNDR | hsa-miR-200c-3p | Carcinoma ductal breast | MNDR-E-MI-26389 |
MNDR | hsa-miR-200c-3p | Glioblastoma | MNDR-E-MI-26390 |
MNDR | hsa-miR-200c-3p | Glioma | MNDR-E-MI-26391 |
MNDR | hsa-miR-200c-3p | Epilepsy temporal lobe | MNDR-E-MI-26392 |
MNDR | hsa-miR-200c-3p | Breast carcinoma | MNDR-E-MI-26393 |
MNDR | hsa-miR-200c-3p | Liver neoplasms | MNDR-E-MI-26394 |
MNDR | hsa-miR-200c-3p | Cervical adenocarcinoma | MNDR-E-MI-26395 |
MNDR | hsa-miR-200c-3p | Ovarian adenocarcinoma | MNDR-E-MI-26396 |
MNDR | hsa-miR-200c-3p | Gastric adenocarcinoma | MNDR-E-MI-26397 |
MNDR | hsa-miR-200c-3p | Cervical squamous cell carcinoma | MNDR-E-MI-26398 |
MNDR | hsa-miR-200c-3p | Pituitary adenoma | MNDR-E-MI-26399 |
MNDR | hsa-miR-200c-3p | Lung squamous cell carcinoma | MNDR-E-MI-26400 |
MNDR | hsa-miR-200c-3p | Non-small cell lung cancer | MNDR-E-MI-26401 |
MNDR | hsa-miR-200c-3p | Lung adenocarcinoma | MNDR-E-MI-26402 |
MNDR | hsa-miR-200c-3p | Thyroid carcinoma | MNDR-E-MI-26403 |
MNDR | hsa-miR-200c-3p | Ovarian carcinoma | MNDR-E-MI-26404 |
MNDR | hsa-miR-200c-3p | Bladder urothelial carcinoma | MNDR-E-MI-26405 |
MNDR | hsa-miR-200c-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-26406 |
MNDR | hsa-miR-200c-3p | Carcinoma renal cell | MNDR-E-MI-26407 |
MNDR | hsa-miR-200c-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-26408 |
MNDR | hsa-miR-200c-3p | Clear cell renal cell carcinoma | MNDR-E-MI-26409 |
MNDR | hsa-miR-200c-3p | Large cell carcinoma | MNDR-E-MI-26410 |
MNDR | hsa-miR-200c-3p | Biliary tract cancer | MNDR-E-MI-26411 |
MNDR | hsa-miR-200c-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-26412 |
MNDR | hsa-miR-200c-3p | Cholangiocarcinoma | MNDR-E-MI-26413 |
MNDR | hsa-miR-200c-3p | Esophageal cancer | MNDR-E-MI-26414 |
MNDR | hsa-miR-200c-3p | Uterus leiomyosarcoma | MNDR-E-MI-26415 |
MNDR | hsa-miR-200c-3p | Prolactinoma | MNDR-E-MI-26416 |
MNDR | hsa-miR-200c-3p | Lung small cell carcinoma | MNDR-E-MI-26417 |
MNDR | hsa-miR-200c-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-26418 |
MNDR | hsa-miR-200c-3p | Testicular germ cell cancer | MNDR-E-MI-26419 |
MNDR | hsa-miR-200c-3p | T acute lymphoblastic leukemia | MNDR-E-MI-26420 |
MNDR | hsa-miR-200c-3p | Acute t cell leukemia | MNDR-E-MI-26421 |
MNDR | hsa-miR-200c-3p | Ovarian endometrial cancer | MNDR-E-MI-26422 |
MNDR | hsa-miR-200c-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-26423 |
MNDR | hsa-miR-200c-3p | Breast invasive carcinoma | MNDR-E-MI-26424 |
MNDR | hsa-miR-200c-3p | Hepatocellular carcinoma | MNDR-E-MI-26425 |
MNDR | hsa-miR-200c-3p | Familiar ovarian carcinoma | MNDR-E-MI-26426 |
MNDR | hsa-miR-200c-3p | B-cell lymphoma | MNDR-E-MI-26427 |
MNDR | hsa-miR-200c-3p | Retinoblastoma | MNDR-E-MI-26428 |
MNDR | hsa-miR-200c-3p | Hodgkin lymphoma | MNDR-E-MI-26429 |
MNDR | hsa-miR-200c-3p | Burkitt lymphoma | MNDR-E-MI-26430 |
MNDR | hsa-miR-200c-3p | Crohn disease | MNDR-E-MI-26431 |
MNDR | hsa-miR-200c-3p | Skin cutaneous melanoma | MNDR-E-MI-26432 |
MNDR | hsa-miR-200c-3p | Skin melanoma | MNDR-E-MI-26433 |
MNDR | hsa-miR-200c-3p | Systemic lupus erythematosus | MNDR-E-MI-26434 |
MNDR | hsa-miR-200c-3p | Acute myelocytic leukemia | MNDR-E-MI-26435 |
MNDR | hsa-miR-200c-3p | Colorectal cancer | MNDR-E-MI-26436 |
MNDR | hsa-miR-200c-3p | Nasopharynx carcinoma | MNDR-E-MI-26437 |
MNDR | hsa-miR-200c-3p | Multiple myeloma | MNDR-E-MI-26438 |
MNDR | hsa-miR-200c-3p | Ovarian epithelial cancer | MNDR-E-MI-26439 |
MNDR | hsa-miR-200c-3p | Epstein-barr virus infections | MNDR-E-MI-26440 |
MNDR | hsa-miR-200c-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-26441 |
MNDR | hsa-miR-200c-3p | Breast cancer her3+ negative | MNDR-E-MI-26442 |
MNDR | hsa-miR-200c-3p | Renal childhood neoplasms | MNDR-E-MI-26443 |
MNDR | hsa-miR-200c-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-26444 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA2 | Homo sapiens | RR00022406 |
TOP